Use of nonsteroidal antiinflammatory drugs: Is there a change in patient risk profile after withdrawal of rofecoxib?

Journal of Rheumatology

Volumn 38, Issue 2, 2011, Pages 195-202

  Rahme, Elham ^a   Roussy, Jean Pascal ^b   Lafrance, Jean Philippe ^c   Nedjar, Hacene ^a   Morin, Suzanne ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b PFIZER INC   (United States)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Nonsteroidal antiinflammatory drugs; Patient risk; Rofecoxib

Indexed keywords

CELECOXIB; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYPHENBUTAZONE; PHENYLBUTAZONE; PIROXICAM; SALSALATE; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TOLMETIN;

ADULT; AGED; ARTHRITIS; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG CHOICE; DRUG USE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CANADA; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; ODDS RATIO; RISK; RISK FACTORS;

EID: 79551708807     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100332     Document Type: Review

References (33)

1. Rahme E, Marentette MA, Kong SX, LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated co-prescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.
2. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 17;352:1092-102. (Pubitemid 40365350)
3. Rahme E, Nedjar H, Bizzi A, Morin S. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther 2007;26:1387-98. (Pubitemid 350045614)
4. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296:1633-44.
5. Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004;19:197-208.
6. Health Canada. Basic product monograph information for nonsteroidal anti-inflammatory drugs. [Internet. Accessed September 27, 2010.] Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/nsaid- ains/nsaids-ains-eng.php
7. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909.
8. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57. (Pubitemid 43054294)
9. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009;104:728-38.
10. Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009;29:481-96.
11. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008;103:2908-18.
12. Schnitzer TJ, Weaver AL, Polis AB, Petruschke RA, Geba GP. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. J Rheumatol 2005;32:1093-105.
13. Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis AB, et al. Pain management in osteoarthritis: a focus on onset of efficacy - a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain 2004;5:511-20.
14. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931-9.
15. Quigley C. Opioid switching to improve pain relief and drug tolerability [review]. Cochrane Database Syst Rev 2004;CD004847.
16. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
17. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366-9. (Pubitemid 40839565)
18. L'usage des anti-inflammatoires non stéroïdiens (AINS) chez les adultes québécois. Quebec: Conseil du medicament; 2009. [Internet. Accessed September 27, 2010.] Available from: http://www.cdm.gouv.qc. ca/site/download.php?f=fdcff7cbf1d671124c0f75328676e6ed
19. Régie de l'assurance maladie du Québec. Population registered with the RAMQ drug plan. Internet. Available from: http://www.ramq.gouv.qc.ca/fr/statistiques/index.shtml
20. Rahme E, Nedjar H, Bizzi A, Morin S. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among seniors also using NSAIDs: a retrospective cohort study. Aliment Pharmacol Ther 2007;26:1387-98.
21. Weisberg S. Applied linear regression. 3rd ed. New York: John Wiley & Sons, Inc.; 2005.
22. Thiebaud P, Patel BV, Nichol MB. Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. Value Health 2006;9:361-8.
23. Alacqua M, Trifiro G, Cavagna L, Caporali R, Montecucco CM, Moretti S, et al. Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. Arthritis Rheum 2008;59:568-74.
24. Taha AS, Angerson WJ, Prasad R, McCloskey C, Blatchford O. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther 2007;26:1171-8. (Pubitemid 47480957)
25. Williams D, Singh M, Hind C. The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. Br J Clin Pharmacol 2006;62:366-8.
26. Schussel K, Schulz M. Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. Pharmazie 2006;61:878-86.
27. Sukel MP, van der Linden MW, Chen C, Erkens JA, Herings RM. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf 2008;17:9-19. (Pubitemid 351166613)
28. Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. Curr Med Res Opin 2007;23:1859-66.
29. Elnachef N, Scheiman JM, Fendrick AM, Howden CW, Chey WD. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. Aliment Pharmacol Ther 2008;28:1249-58.
30. Setakis E, Leufkens HG, van Staa TP. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis Rheum 2008;59:1105-11.
31. Teeling M, O'Connor H, Feely J, Bennett K. What therapies have replaced rofecoxib in Ireland? Br J Clin Pharmacol 2007;64:536-41.
32. Usher C, Bennett K, Teeling M, Feely J. Characterizing new users of NSAIDs before and after rofecoxib withdrawal. Br J Clin Pharmacol 2007;63:494-7.
33. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.